ELCC 2022 – Jordi Remon

Jordi Remon outlines what needs to be considered in the context of neoadjuvant and adjuvant immunotherapy in patients with resectable lung cancer, how tyrosine kinase inhibitors can contribute to effective perioperative treatment, treatment approaches in patients with oncogene-driven lung cancer who develop brain metastases as well as in patients with CNS affection whose tumors do not harbor genetic drivers. Current challenges in selecting the best immunotherapeutic approach for the individual patient with mNSCLC and how to deal with them as well as promising potential predictive biomarkers of ICI in patients with NSCLC are highlighted, too.

Here is the full ELCC 2022 report.